Effect of recombinant human endostatin on the clinical treatment of malignant cavity effusion

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17011666

Enrollment

Unknown

Registered

2017-06-14

Start date

2010-05-01

Completion date

Unknown

Last updated

2017-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant cavity effusion

Interventions

monotherapy group:only given Endostar

combination group:Endostar combined with cisplatin

control group:only treated with cisplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patients were pathologically diagnosed with primary tumor; 2. The collected patients were confirmed as tumors with malignant effusion; 3. The patients did not receive chemotherapy or radiotherapy within the latest two months after the operation treatment; 4. The Karnofsky scores of patients were all over 40 and their expected survival time was more than 3 months.

Exclusion criteria

Exclusion criteria: (1) Functional impairment of major organs; (2) Received cavity injection drugs before the study; (3) Age under 18 years

Design outcomes

Primary

Measure	Time frame
complete response;partial response;progressive disease;objective response rate;overall survival;progression-free survival;adverse reactions;Karnofsky performance status;	—

Countries

China

Contacts

Public ContactLiang Wenbo

Dalian University

wenbosr@163.com+86 15964049947

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026